Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease

Expert Opinion on Drug Safety

Volumn 10, Issue 6, 2011, Pages 863-870

  Selinger, Christian P ^a,b   Robinson, Andrew ^a   Leong, Rupert W ^b  

^a HOPE HOSPITAL   (United Kingdom)

^b ANZAC Research Institute   (Australia)

Author keywords

Adherence; Adverse events; Inflammatory bowel disease; Maintenance medication

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GASTROINTESTINAL AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ANXIETY; CROHN DISEASE; DEMOGRAPHY; DISEASE EXACERBATION; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; ENTERITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REMISSION; REVIEW; SOCIOECONOMICS; TREATMENT PLANNING; TREATMENT REFUSAL; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

COHORT STUDIES; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICATION ADHERENCE; PHYSICIAN-PATIENT RELATIONS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 80054768014     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.583915     Document Type: Review

References (44)

1. Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;10(Suppl V):v1-16
2. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006;51:2165-9
3. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003;98:S6-17
4. Hanauer S, Present DH, Jones WK, et al. The state of the art in the management of inflammatory bowel disease: update and recent advances in colorectal cancer prevention. Clin Courier 2004;22:1-8
5. Dignass A, Van Asche G, Lindasy JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010;4:28-62
6. Travis SPL, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62 (Pubitemid 351179488)
7. D'Haens G, Baert F, van Assche G, et al. Belgian inflammatory bowel disease research group; north-holland gut club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7 (Pubitemid 351284485)
8. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
9. Biancone L, Michetti P, Travis S, et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohn's Colitis 2008;2:63-92 (Pubitemid 351179489)
10. Horne R, Weinman J, Barber N, et al. Concordance, adherence and complicance in medicine taking: a conceptual map and research priorities. National Institute for Health Research Service Delivery and Organisation R&D, London; 2006
11. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:191-8 (Pubitemid 36951655)
12. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33 (Pubitemid 32959535)
13. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007;26:217-25 (Pubitemid 46985496)
14. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007;13:1244-9 (Pubitemid 47597771)
15. Cerveny P, Bortlik M, Vlcek J, et al. Non-adherence to treatment in inflamatory bowel disease in Czech Republic. J Crohn's Colitis 2007;1:77-81 (Pubitemid 350265734)
16. Dewulf NDLS, Monteiro RA, Passos ADC, et al. Compliance to drug therapy in inflammatory bowel diseases outpatients from an university hospital [Portuguese]. Arq Gastroenterol 2007;44:289-96 (Pubitemid 351328625)
17. D'Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008;27:166-72 (Pubitemid 350256604)
18. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102:1417-26 (Pubitemid 46976288)
19. Horne R, Parham R, Driscoll R, et al. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837-44
20. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1:170-3 (Pubitemid 37248066)
21. Karbach U, Degen I, Ewe K. Extent of drug compliance in Crohn disease patients-study of a special ambulatory care unit of a university clinic. Z Gastroenterol 1984;22:573-9
22. Lopez San Roman A, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005;97:249-57 (Pubitemid 40755660)
23. Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis 2007;13:446-50 (Pubitemid 46668250)
24. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in infl ammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001;32:66-8 (Pubitemid 32038115)
25. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44 (Pubitemid 36875345)
26. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patientswith infl ammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005;19:235-44 (Pubitemid 40778865)
27. Bhatt J, Patil S, Joshi A, et al. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol 2009;28:143-6
28. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43 (Pubitemid 36126514)
29. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29(3):247-57
30. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53(4):1020-4 (Pubitemid 351379831)
31. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment. JAMA 2002;288:2880-3
32. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008:CD000011
33. Wroe LE. Intentional and unintentional nonadherence: a study of decision making. J Behav Med 2002;25:355-72
34. Bermejo F, Lopez-San Roman A, Algaba A, et al. Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn's Colitis 2010;4:422-6
35. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and Psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO study. Inflamm Bowel Dis 2010. [Epub ahead of print]
36. Moshkovska T, Stone MA, Clatworthy J, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther 2009;30:1118-27
37. Trindade A, Ehrlich A, Kornbluth A, et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2010. [Epub ahead of print]
38. Lakatos PL, Czegledi Z, David G, et al. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis 2010;4(3):283-90
39. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008;27:1157-66 (Pubitemid 351697281)
40. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. Am J Pharm Assoc (Wash) 2003;43:668-78
41. Robinson GL, Gilbertson AD, Litwack L. The effects of a psychiatric patient education to medication program on post discharge compliance. Psychiatric Q 1987;58:113-18 (Pubitemid 17032437)
42. Bregenzer A, Lange A, Fuerst A. Patient education in inflammatory bowel disease does not influence patients knowledge and long-term psychosocial well-being. Z Gastroenterol 2005;43:367-71 (Pubitemid 40593381)
43. Moss AC, Chaudhary N, Tukey M, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis-a prospective study. J Crohn's Colitis 2010;4:171-5
44. Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis 2011. [Epub ahead of print]